Kailera Therapeutics Shares Slump 10% on 62% Nausea, 38% Vomiting Rate
KLRA•Shares of Kailera Therapeutics fell 10% after Phase 3 data revealed 62% of participants experienced moderate-to-severe nausea and 38% reported vomiting. The trial still showed an average 11% body weight reduction at 24 weeks but safety concerns now cast doubt on approval timeline.
1. Trial Results
Late-stage Phase 3 data revealed that 62% of participants experienced moderate-to-severe nausea and 38% reported vomiting, while patients achieved an average 11% reduction in body weight over 24 weeks.
2. Market Reaction
Kailera Therapeutics shares tumbled 10% in one trading session as investors reassessed the drug’s safety profile, triggering elevated trading volume and heightened stock volatility.
3. Safety Profile
The high incidence of gastrointestinal adverse events raises regulatory scrutiny, potentially requiring additional studies, expanded safety monitoring or prominent label warnings before approval.
4. Next Steps
The company plans to engage with health authorities to address safety concerns, prepare detailed data presentations for upcoming medical conferences, and adjust its New Drug Application timeline accordingly.
